MALVERN, PA — TELA Bio Inc. (NASDAQ: TELA) reported an 8% decline in third-quarter revenue to $19 million as weaker sales of its reconstructive surgery products weighed on results, prompting the Malvern medical technology company to pursue $17 million in annual cost reductions aimed at extending its cash reserves into 2028.
Revenue fell from $20.7 million in the third quarter of 2025, primarily because of lower sales volumes for the company’s OviTex PRS products. International revenue increased 18% from a year earlier, partially offsetting the decline.
TELA Bio reported a net loss of $9.3 million, or $0.16 per share, for the quarter ended September 30, compared with a loss of $8.6 million, or $0.19 per share, a year earlier.
The company ended September with $22.7 million in cash and cash equivalents, making expense reductions central to its efforts to stabilize operations and restore revenue growth.
TELA Bio implemented a strategic cost reduction initiative targeting $17 million in annual operating expense savings. Management expects the restructuring to extend its cash runway into 2028 while allowing resources to be redirected toward commercial growth.
Operating expenses, excluding other expenses, declined 17.5% to $17.6 million from $21.4 million in the prior-year quarter.
The company’s operating loss narrowed to $7.3 million from $7.6 million a year earlier. Compared with the second quarter of 2026, the operating loss decreased by $2 million, or 21%, including costs associated with the restructuring.
Adjusted earnings before interest, taxes, depreciation and amortization remained negative at $3.4 million, compared with a $5.7 million loss in the third quarter of 2025.
That represented a 39% improvement from a year earlier and a $4.3 million, or 55%, reduction from the second quarter.
On an adjusted basis, TELA Bio reported a net loss of $7.3 million, or $0.13 per share, compared with $8.4 million, or $0.18 per share, in the prior-year period.
Profitability remained under pressure despite lower operating expenses.
Gross profit declined to $12.3 million from $14 million, while gross margin contracted to 64.9% from 67.5%.
The company attributed the margin decline primarily to higher charges for excess and obsolete inventory. Excluding $1.1 million in noncash charges, TELA Bio calculated an adjusted gross margin of approximately 71%.
Heather Getz, who recently assumed the chief executive officer position, said her first quarter leading the company focused on developing a strategy to restore growth while reducing expenses.
“Our cost reduction initiative allows us to thoughtfully reallocate resources, supports a return to topline growth, and extends our cash runway,” Getz said.
The company reported sequential revenue growth in its U.S. hernia repair business and continued year-over-year growth in Europe, even as lower OviTex PRS volumes reduced consolidated revenue.
TELA Bio also reported commercial gains across its OviTex hernia repair portfolio, although those gains were insufficient to offset the overall revenue decline.
Beyond its financial restructuring, the company received U.S. Food and Drug Administration 510(k) clearance for its Liora Monofilament Scaffold, a device intended for soft tissue reinforcement.
The clearance adds another product to TELA Bio’s portfolio of surgical reconstruction technologies.
The company also cited four peer-reviewed clinical publications reporting favorable outcomes involving its OviTex and OviTex PRS products, which are used in hernia repair and other soft tissue reconstruction procedures.
TELA Bio regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Global Market, resolving a separate exchange-listing issue.
The company’s immediate priorities remain reducing operating losses, managing cash consumption and rebuilding sales following a quarter in which cost reductions improved operating performance but did not prevent a decline in revenue or a larger net loss.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.
